FcyRIIa is an activatory receptor and contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain, involved in the initiation of
signalling events. There is now strong evidence from transgenic mouse models and human genetic susceptibility studies that implicate FcyRIIa in a number of immune
diseases including, rheumatoid arthritis, systemic lupus erythematosus (SLE) and immune thrombocytopenia purpura (ITP). FcyRHa is therefore a promising target for the development of therapeutics to treat these diseases.